Acute Myeloid Leukemia With KMT2A Amplification: A TP53-Alteration-Enriched Subgroup Associated With Chromoanagenesis and Poor Prognosis.
Identifying a high-risk acute myeloid leukemia subtype resistant to standard chemotherapy highlights the urgent need for new targeted treatments.
This PubMed record reports a retrospective observational study on Acute Myeloid Leukemia With KMT2A Amplification: A TP53-Alteration-Enriched Subgroup Associated With Chromoanagenesis and Poor Prognosis. The authors report that its refractoriness to conventional chemotherapy highlights the urgent need for more effective, targeted therapeutic strategies.
What the study was
- Study design
- Retrospective observational study
- Population
- Human participants or clinical records described in the abstract
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Why it surfaced
Retrospective observational study with direct human relevance was scored conservatively from PubMed abstract and citation metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.